Rockville, Maryland — September 23, 2026 — The global uveal melanoma treatment market is valued at USD 1.7 billion in 2026 and is projected to reach USD 3.4 billion by 2036, expanding at a 7.3% CAGR during the 2026–2036 forecast period, according to Fact.MR. Growth is being supported by established eye-preserving radiation, disease-specific systemic treatment for metastatic disease, liver-directed treatment, and development of targeted therapies. The 2026 ESMO-EURACAN clinical practice guideline identifies plaque brachytherapy and proton beam radiotherapy as established local treatments, keeping ocular radiation central to primary disease management.
Fact.MR also identifies the emergence of disease-specific systemic treatment as an important market development. Tebentafusp is an established first-line option for eligible patients with HLA-A*02:01-positive unresectable or metastatic uveal melanoma, while liver-directed treatment has gained another pathway through the FDA-approved HEPZATO KIT for selected adults with unresectable hepatic metastases.
Get detailed market forecasts, competitive benchmarking, and pricing trends:
Global Segment Leaders
- Product — Radiation Therapy: 34.8% share in 2026. Plaque brachytherapy and external beam approaches provide local tumor control while enabling eye preservation in selected patients with localized disease.
- Disease Stage — Primary Uveal Melanoma: 63.5% share in 2026. Treatment generally begins with control of the ocular primary through brachytherapy, proton therapy, local resection, or enucleation, depending on tumor characteristics and visual potential.
- Route of Administration — Intravenous: 46.9% share in 2026. Advanced disease treatment includes infused therapies such as tebentafusp and checkpoint inhibitors, keeping intravenous administration central to systemic care.
- End Use — Hospitals: 48.6% share in 2026. Hospitals provide the specialist infrastructure required for radiation, surgery, monitored infusions, liver-directed procedures, imaging, and multidisciplinary oncology care.
- Patient Age Group — Adult Patients: 69.3% share in 2026. Uveal melanoma is primarily diagnosed in adults, with incidence increasing with age, while pediatric disease remains uncommon.
Country-Level Performance
| Country | CAGR | Key Growth Driver |
| Germany | 8.4% | The G-BA completed a 2024 reassessment of tebentafusp for HLA-A*02:01-positive unresectable or metastatic uveal melanoma, while German centers also participate in the Phase 3 ATOM adjuvant study. |
| Brazil | 7.7% | ANVISA granted a new-product registration for tebentafusp in February 2025 for eligible adults with unresectable or metastatic uveal melanoma. |
| USA | 6.9% | The FDA approved tebentafusp in 2022 and HEPZATO KIT in 2023, creating systemic and liver-directed treatment pathways. |
| UK | 6.2% | NICE recommended tebentafusp in January 2025 for eligible adults, establishing a funded NHS pathway for advanced disease. |
| Japan | 5.5% | A 2025 analysis of Japan’s National Cancer Registry found uveal melanoma represented 2.7% of melanoma cases in 2016–2017, concentrating treatment in specialist centers and making precision-oncology access important. |
Regional Context
Germany and Brazil are the faster-growing country markets among those profiled by Fact.MR, with CAGRs of 8.4% and 7.7%, respectively. Germany benefits from an established health-technology assessment pathway for disease-specific therapy, while Brazil’s February 2025 ANVISA registration of tebentafusp created a national regulatory route for eligible patients with unresectable or metastatic disease.
The USA and UK are projected to expand at 6.9% and 6.2%, respectively. U.S. growth is supported by FDA-approved systemic and liver-directed treatment options as well as ongoing registrational development, while the UK has a defined funded NHS pathway for eligible patients following NICE’s January 2025 recommendation of tebentafusp. Japan, at 5.5%, has a comparatively small uveal melanoma patient pool, making specialist referral, precision-oncology access, and participation in international clinical development important to market expansion.
The full report covers North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East & Africa, with country-level analysis for Germany, Brazil, USA, UK, and Japan. Fact.MR states that its analysis draws on more than 120 public and technical sources, more than 35 company and treatment portfolios, and more than 20 industry interviews across at least 25 countries.
Competitive Landscape
Key companies profiled by Fact.MR include Immunocore Holdings plc, Delcath Systems, Inc., IDEAYA Biosciences, Inc., Servier, Aura Biosciences, Inc., Merck & Co., Inc., and Bristol Myers Squibb. Competition is differentiated by disease stage, HLA status, metastatic distribution, route of administration, and access to specialist treatment infrastructure.
Recent developments highlighted by the report include IDEAYA Biosciences and Servier’s 2026 positive registrational data for darovasertib plus crizotinib in HLA-A*02:01-negative metastatic uveal melanoma, with U.S. filing activity underway. In June 2026, Aura Biosciences completed enrollment in its Phase 3 CoMpass study of bel-sar for early choroidal melanoma, with topline data expected in 2027.
Immunocore continues the Phase 3 ATOM adjuvant study of tebentafusp, while Delcath Systems provides HEPZATO KIT for selected patients with unresectable hepatic metastases, adding a liver-directed treatment pathway alongside systemic therapy.
Explore More Related Studies Published by Fact.MR Research
Color Correcting Glasses Market
About Fact.MR
Fact.MR is a leading provider of market research and consulting services, offering syndicated and customized research across industries including healthcare, pharmaceuticals, and medical devices.
For more information on the full report, visit: Uveal Melanoma Treatment Market
